Malestar emocional de pacientes y familiares en la Unidad de Cuidados Paliativos de un hospital general: un estudio piloto

María José Zamora Muñoz(Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana), Jesús Rodríguez Marín(Hospital General Universitario de Alicante Doctor Balmis), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Carlos J. van-der Hofstadt Román(Universitat de Miguel Hernández d'Elx), Manuel Valladares(American Society of Clinical Oncology)
Medicina Paliativa
February 3, 2018
10.1016/j.medipa.2017.03.006
Cited by 7

Related Papers

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
|The Oncologist|2012|213
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
|Journal of Clinical Oncology|2005|98
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
|The Oncologist|2012|88
Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study
|The Lancet HIV|2020|71